Nakai K, Fujii T, Fujimoto K, Suzuki T, Kawashima K
Department of Pharmacology, Kyoritsu College of Pharmacy, Tokyo, Japan.
Neurosci Res. 1998 May;31(1):23-9. doi: 10.1016/s0168-0102(98)00019-4.
The mechanisms involved in the enhancement of acetylcholine (ACh) release in the rat hippocampus by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a serotonin (5-HT)1A receptor agonist, were investigated using in vivo microdialysis. Administration of p-chlorophenylalanine (PCPA, 300 mg/kg, i.p.), a tryptophan hydroxylase inhibitor, 3 days before the dialysis experiments reduced the hippocampal 5-HT content to 30% of that in saline-treated rats, but did not affect basal ACh release in the hippocampus. 8-OH-DPAT administered systemically (0.5 mg/kg, s.c.) or applied locally (30 microM) into the hippocampus through the dialysis probe significantly enhanced the release of ACh in the hippocampus of PCPA-treated rats to the same degree as that in saline-treated rats. Pretreatment with (+)WAY-100135 (5 mg/kg, i.p.), a selective 5-HT1A receptor antagonist, completely eliminated the enhancement of ACh release induced by locally applied 8-OH-DPAT, but only partially reduced the effects induced by systemically administered 8-OH-DPAT, in both groups of rats. Systemically administered 8-OH-DPAT induced hyperlocomotion in the both saline- and PCPA-treated rats, but this was not eliminated by (+)WAY-100135. 8-OH-DPAT applied locally into the hippocampus did not elicit hyperlocomotion in either group of rats. These results suggest that the modification of endogenous 5-HT release via the 5-HT1A autoreceptor is not involved in the 8-OH-DPAT-induced increase of hippocampal ACh release, and that the increase of ACh release induced by locally applied 8-OH-DPAT involves mainly hippocampal postsynaptic 5-HT1A receptor stimulation. In addition, a possibility that subtypes of 5-HT receptors other than the 5-HT1A receptor, probably 5-HT7 receptor in the septum as well as postsynaptic 5-HT1A receptor in the hippocampus, are involved in the increased hippocampal ACh release induced by systemically administered 8-OH-DPAT is discussed.
利用体内微透析技术,研究了5-羟色胺(5-HT)1A受体激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)增强大鼠海马中乙酰胆碱(ACh)释放的机制。在透析实验前3天,腹腔注射色氨酸羟化酶抑制剂对氯苯丙氨酸(PCPA,300mg/kg),可使海马中5-HT含量降至生理盐水处理大鼠的30%,但不影响海马中ACh的基础释放。全身给药(0.5mg/kg,皮下注射)或通过透析探针局部给药(30μM)至海马的8-OH-DPAT,可使PCPA处理大鼠海马中ACh的释放增强至与生理盐水处理大鼠相同的程度。在两组大鼠中,预先腹腔注射选择性5-HT1A受体拮抗剂(+)WAY-100135(5mg/kg),可完全消除局部应用8-OH-DPAT诱导的ACh释放增强,但仅部分降低全身给药8-OH-DPAT的作用。全身给药8-OH-DPAT可使生理盐水处理和PCPA处理的大鼠均出现运动亢进,但(+)WAY-100135不能消除这种现象。局部应用于海马的8-OH-DPAT在两组大鼠中均未引起运动亢进。这些结果表明,通过5-HT1A自身受体改变内源性5-HT释放不参与8-OH-DPAT诱导的海马ACh释放增加,且局部应用8-OH-DPAT诱导的ACh释放增加主要涉及海马突触后5-HT1A受体刺激。此外,还讨论了除5-HT1A受体外的5-HT受体亚型,可能是隔区的5-HT7受体以及海马中的突触后5-HT1A受体,参与全身给药8-OH-DPAT诱导的海马ACh释放增加的可能性。